Latest filing published 02 Mar 2023 for Abbott Laboratories.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Sammy Karam: trading record in brief
Sammy Karam (senior executive) discloses dealings in Abbott Laboratories to SEC (Form 4). Over a trading history stretching from 16 February 2019 to 28 February 2023, the count stands at 22 filings.
No open-market purchase appears, only 5 sales worth €3.6M. Outside the open market, there are 14 share grants and 3 option exercises. Since January 2023: no purchases and 1 sale on the market.
The newest entry dates from 2 March 2023: a share grant of €65k, in Abbott Laboratories. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Companies and markets linked to Sammy Karam
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 12,322 shares0Common shares without par valueSEC:0001415889-23-003909:0
- 4,200 shares@ US$108.7511.8% of flowCommon shares without par valueSEC:0001415889-23-000127:0
- 13,238 shares0Common shares without par valueSEC:0001415889-22-002194:0
- 4,700 shares@ US$140.004928.5% of flowCommon shares without par valueSEC:0001415889-21-006264:0
- 8,000 shares@ US$75.9025.4% of flowCommon shares without par valueSEC:0001415889-21-004019:0
- 8,000 shares@ US$75.9025.1% of flowCommon shares without par valueSEC:0001415889-21-003804:0
6 of 6 declarations
